Thyroid Eye Disease (TED) Market Predicted to Show Remarkable Growth by 2032, Analyzes DelveInsight | Key companies: Viridian Therapeutics, Novartis, Immunovant Sciences

Thyroid Eye Disease (TED) Market Predicted to Show Remarkable Growth by 2032, Analyzes DelveInsight |  Key companies: Viridian Therapeutics, Novartis, Immunovant Sciences
Thyroid Eye Disease (TED) Market Predicted to Show Remarkable Growth by 2032, Analyzes DelveInsight |  Key Companies - Viridian Therapeutics, Novartis, Immunovant Sciences

Delve Insight Business Research LLP

According to DelveInsight, the size of the Thyroid Eye Disease (TED) market is expected to grow in the coming years due to the increase in the prevalent population in the 7MM and the launch of emerging therapies. Globally, several key companies are active in the therapeutic domain of thyroid eye disease, and therapies in development are focused on novel approaches to treating the disease.

DelveInsight’s “Thyroid Eye Disease (TED) Market Outlook, Epidemiology and Market Forecast 2032The report offers an in-depth understanding of the disease, historical and forecast epidemiology, as well as Thyroid Eye Disease market size, share and trends in the top seven (7MM) markets (i.e. US, EU5 (Germany , Spain, Italy, France and the United Kingdom) and Japan).

The Thyroid Eye Disease Market Report Covers Emerging Drugs, Current Treatment Practices, Individual Therapies Market Share, And Current And Forecast Market Size From 2019 To 2032. It Also Evaluates Current Treatment Practice/Algorithm, Key Drivers, And Market Sizes. barriers affecting market growth. and unmet medical needs to select the best opportunities and assess the underlying market potential.

Thyroid Eye Disease Market

Thyroid Eye Disease (TED): An Overview

Thyroid eye disease (TED) is a complex orbital inflammatory disease that can be sight-threatening, debilitating and disfiguring. TED is also known as Graves’ ophthalmopathy, named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman with a goiter, rapid heartbeat, and exophthalmos.

TED affects the eye muscles, eyelids, lacrimal glands, and fatty tissues behind the eye so that they become inflamed. This can cause the eyes and lids to become red, puffy, and uncomfortable, and the eyes may be pushed forward (“staring” or “bulging” eyes).

Key facts of the thyroid eye disease (TED) market

  • According to NORD, the exact prevalence of thyroid eye disease is unknown, but it is estimated to be 16 per 100,000 women in the general population and 2.9 per 100,000 men in the general population.

  • According to a study by Bahn et al. (2019), in approximately 40% of patients with TED, ocular and systemic symptoms have a simultaneous onset.

  • According to Carla et al. (2020), the worldwide prevalence in patients with thyroid eye disease was 10.36% for hypothyroidism, 7.9% for euthyroidism, and 86.2% due to hyperthyroidism.

  • The 7MM companies are persistently working to develop novel treatment therapies to address thyroid eye disease.

  • There are several promising drugs in the pipeline including VRDN—001 (Viridian Therapeutics), Secukinumab (Novartis)Y IMVT-1401 (Immune Sciences GmbH), among others. VRDN-001 is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor receptor 1 (IGF-1R).

  • Key players are strengthening their position in the market through strategic mergers, agreements, and acquisitions that are expected to drive the growth of the thyroid eye disease treatment market during the forecast period (2022-2032).

Thyroid Eye Disease (TED) Market

The market outlook section of the report helps build a detailed understanding of the historical, current and forecast situation. Thyroid Eye Disease Market Size by analyzing the impact of current and emerging therapies in development. It also provides a comprehensive assessment of market drivers and barriers, unmet needs, and emerging technologies that will impact market dynamics.

The report gives full details of the Market trend Thyroid Eye Disease for each marketed drug and mid-stage and late-stage therapies evaluating their impact based on the annual cost of therapy, its mechanism of action (MoA), route of administration (RoA), types of molecules, competition with other therapies, brand value , and its impact on the market.

Epidemiological evaluation of thyroid eye disease (TED)

The epidemiology section provides information on historical, current, and forecast epidemiological trends in the seven major countries (7MM) from 2019 to 2032. It helps recognize the causes of current and forecast epidemiological trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of the diagnosed and prevalent patient pool, future trends, and the views of key opinion leaders.

Epidemiological segmentation of thyroid eye disease (TED)

Thyroid Eye Disease Specific Gravity Cases

Diagnosed and treatable cases of thyroid eye disease

Gender-Specific Cases of Thyroid Eye Disease

Age-Specific Cases of Thyroid Eye Disease

Total prevalent cases of thyroid eye disease

Thyroid Eye Disease (TED) Drug Uptake and Development Activities

The drug consumption section focuses on the consumption rate of potential drugs recently launched in the Thyroid Eye Disease Market or is expected to be released during the study period. The analysis covers Thyroid Eye Disease market uptake of drugs, patient uptake of therapies, and sales of each drug.

In addition, the therapeutic evaluation section helps to understand the drugs with the fastest absorption and the reasons behind the maximum use of the drugs. Also, compare drugs based on market share.

The report also covers the Thyroid Eye Disease Pipeline Development Activities. It provides valuable information on different therapeutic candidates at various stages and the key companies involved in the development of targeted therapies. It also discusses recent developments such as collaborations, acquisitions, mergers, patent licensing details, and other information for emerging therapies.

Learn how the thyroid eye disease market will evolve by 2032 @

https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market

Therapeutic Analysis of Thyroid Eye Disease (TED)

Companies across 7MM are persistently working to develop new treatment therapies that can address thyroid eye disease. There are several promising drugs in the pipeline that are expected to be launched in the next few years.

Some of the key companies in the Thyroid Eye Disease (TED) Therapeutics market include:

  • Viridian therapeutics

  • Novartis

  • Immunovant Sciences GmbH

And many others

Therapies for thyroid eye disease (TED) covered in the report include:

  • VRDN—001 (Viridian Therapeutics),

  • Secukinumab (Novartis)

  • IMVT-1401 (Immune Sciences GmbH)

And many more

More emerging medicines and key companies are covered in the report. Download the sample PDF for more information-

https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market

Table of Contents (TOC)

1. Key information

2. Executive Summary

3. Competitive Intelligence Analysis of Thyroid Eye Disease

4. Thyroid Eye Disease Market Overview at a Glance

5. Background and overview of thyroid eye disease

6. Thyroid eye disease patient journey

7. Thyroid Eye Disease Epidemiology and Patient Population (in the US, EU5, and Japan)

8. Thyroid eye disease treatment algorithm, current treatment and medical practices

9. Unmet needs of thyroid eye disease

10. Key endpoints of treatment of thyroid eye disease

11. Products marketed for thyroid eye disease

12. Emerging drugs and latest therapeutic advances for thyroid eye disease

13. Top Seven Thyroid Eye Disease Market Analysis

14. Analysis of attributes

15. Thyroid Eye Disease Market Outlook (in US, EU5 and Japan)

16. Thyroid Eye Disease Access and Reimbursement Summary

17. KOL Views on the Thyroid Eye Disease Market

18. Thyroid Eye Disease Market Drivers

19. Thyroid Eye Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; final content may vary. See the sample report for the full table of contents.

Download the sample PDF to explore the key offerings in the report:

https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market

About DelveInsight
DelveInsight is a leading business consulting and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance.

Other DelveInsight Trending Healthcare Reports

Hypertrophic Cardiomyopathy (HCM) Market

The Hypertrophic Cardiomyopathy (HCM) market research report provides a detailed overview of the historical and forecast epidemiology, size, share, and trends of the Hypertrophic Cardiomyopathy market in the 7MM (ie, the US, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan). In addition, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutic market.

Media contact
Company Name: DelveInsight Business Research LLP
Contact person: Shruti Thakur
Email: Send an e-mail
Telephone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
Condition: Snowfall
Country: USA
Website: https://www.delveinsight.com/

Leave a Comment